| 72.09 -2.44 (-3.27%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 110.23  |
1-year : | 128.19 |
| Resists | First : | 94.38 |
Second : | 109.76 |
| Pivot price | 82.88 |
|||
| Supports | First : | 69.5 |
Second : | 57.82 |
| MAs | MA(5) : | 76.1 |
MA(20) : | 85.53 |
| MA(100) : | 96.86 |
MA(250) : | 74.35  |
|
| MACD | MACD : | -7 |
Signal : | -6 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 4.5 |
| RSI | RSI(14): 14.5 |
|||
| 52-week | High : | 117.87 | Low : | 32.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DNTH ] has closed above bottom band by 0.6%. Bollinger Bands are 37.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 74.57 - 75.28 | 75.28 - 75.72 |
| Low: | 68.03 - 68.93 | 68.93 - 69.48 |
| Close: | 71.03 - 72.54 | 72.54 - 73.45 |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sat, 17 Oct 2026
451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Fri, 16 Oct 2026
Dianthus Therapeutics, Inc. (DNTH) options chain - Yahoo Finance UK
Thu, 15 Oct 2026
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wed, 14 Oct 2026
Dianthus Therapeutics, Inc. (DNTH) Options Chain - Yahoo! Finance Canada
Tue, 13 Oct 2026
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion - Yahoo Finance
Thu, 08 Oct 2026
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Consensus Target Price of $129.83 - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 5.581e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 8,430 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1772e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 79.1 % |
| Return on Equity (ttm) | -17.7 % |
| Qtrly Rev. Growth | 1.9e+006 % |
| Gross Profit (p.s.) | 1634.99 |
| Sales Per Share | -144.84 |
| EBITDA (p.s.) | 1.05556e+007 |
| Qtrly Earnings Growth | -4.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -155 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.5 |
| Price to Cash Flow | 0.6 |
| Dividend | 0 |
| Forward Dividend | 9.14e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|